HK Stock Market Move | HBM HOLDINGS-B (02142) rose more than 7% during trading, winning a lawsuit against Anjin for patent infringement and could receive a maximum compensation of $60.6 million.

HBM HOLDINGS-B (02142) rose more than 7% during the trading day, and as of the time of writing, it has risen by 6.48% to 10.68 Hong Kong dollars, with a trading volume of 22.8611 million Hong Kong dollars. In terms of news, HemBio announced that a jury in the Federal District Court of Delaware in the United States has made a decisive ruling in favor of HemBio in the patent infringement lawsuit brought against Amgen. This ruling signifies a victory for HemBio in the patent litigation, validating the strength of its proprietary transgenic mouse technology and its commitment to protecting scientific innovation. The case against Amgen dates back to 2011. After years of litigation proceedings, on June 8, 2026, the case entered the jury trial phase. After hearing the evidence and closing arguments, the jury in Delaware determined that the defendant had willfully infringed, and that the patents in question were valid. HemBio was awarded full damages of 20 million US dollars. This ruling of willful infringement allows the company to request the judge to increase the compensation amount to triple the original judgment, potentially up to 60.6 million US dollars.